Cargando…

Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients

SIMPLE SUMMARY: The final stages of myeloproliferative neoplasms (MPNs) are related to myelofibrosis (MF). This study aimed to compare secondary myelofibrosis (SMF), overt (PMF), and prefibrotic primary myelofibrosis (pre-PMF) and determine prognostic factors in clinical and genetic features. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tong-Yoon, Kwag, Daehun, Lee, Jong-Hyuk, Lee, Joonyeop, Min, Gi-June, Park, Sung-Soo, Park, Silvia, Jeon, Young-Woo, Yoon, Jae-Ho, Shin, Seung-Hawn, Yahng, Seung-Ah, Cho, Byung-Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Kim, Hee-Je, Min, Chang-Ki, Cho, Seok-Goo, Lee, Jong-Wook, Lee, Jong-Mi, Kim, Myungshin, Lee, Sung-Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496754/
https://www.ncbi.nlm.nih.gov/pubmed/36139644
http://dx.doi.org/10.3390/cancers14184485
_version_ 1784794347185635328
author Kim, Tong-Yoon
Kwag, Daehun
Lee, Jong-Hyuk
Lee, Joonyeop
Min, Gi-June
Park, Sung-Soo
Park, Silvia
Jeon, Young-Woo
Yoon, Jae-Ho
Shin, Seung-Hawn
Yahng, Seung-Ah
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Lee, Seok
Kim, Hee-Je
Min, Chang-Ki
Cho, Seok-Goo
Lee, Jong-Wook
Lee, Jong-Mi
Kim, Myungshin
Lee, Sung-Eun
author_facet Kim, Tong-Yoon
Kwag, Daehun
Lee, Jong-Hyuk
Lee, Joonyeop
Min, Gi-June
Park, Sung-Soo
Park, Silvia
Jeon, Young-Woo
Yoon, Jae-Ho
Shin, Seung-Hawn
Yahng, Seung-Ah
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Lee, Seok
Kim, Hee-Je
Min, Chang-Ki
Cho, Seok-Goo
Lee, Jong-Wook
Lee, Jong-Mi
Kim, Myungshin
Lee, Sung-Eun
author_sort Kim, Tong-Yoon
collection PubMed
description SIMPLE SUMMARY: The final stages of myeloproliferative neoplasms (MPNs) are related to myelofibrosis (MF). This study aimed to compare secondary myelofibrosis (SMF), overt (PMF), and prefibrotic primary myelofibrosis (pre-PMF) and determine prognostic factors in clinical and genetic features. This study included 229 patients; 67 (29%), 122 (53%), and 40 (18%) cases were confirmed as SMF, overt PMF, and pre-PMF, respectively. We compare MFs, including pre-PMF, using six scoring stratifications associated with PMF and one scoring system with SMF. We also evaluated the impact of the genetic groups with clustering methods and previously reported genomic groups. We determined the clinical and genetic features associated with disease progression in SMF, overt PMF, and pre-PMF groups. ABSTRACT: The Philadelphia-negative myeloproliferative neoplasms (MPNs) are divided in three major groups: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 WHO classification incorporates also prefibrotic PMF (pre-PMF) and overt PMF. This study aimed to discriminate the clinical features, genetic alterations, and outcomes in patients with prefibrotic, overt PMF, and secondary MF (SMF). This study included 229 patients with diagnosed myelofibrosis (MF). Among 229 patients, 67 (29%), 122 (53%), and 40 (18%) were confirmed as SMF, overt PMF, and pre-PMF, respectively. The JAK2 V617F mutation was differentially distributed in SMF and PMF, contradictory to CALR and MPL mutations. Regarding nondriver mutations, the occurrence of ASXL1 mutations differed between PMF and SMF or pre-PMF. The three-year overall survival was 91.5%, 85.3%, and 94.8% in SMF, overt PMF, and pre-PMF groups. Various scoring systems could discriminate the overall survival in PMF but not in SMF and pre-PMF. Still, clinical features including anemia and thrombocytopenia were poor prognostic factors throughout the myelofibrosis, whereas mutations contributed differently. Molecular grouping by wild-type SF3B1 and SRSF2/RUNX1/U2AF1/ASXL1/TP53 mutations showed inferior progression-free survival (PFS) in PMF, SMF, and pre-PMF. We determined the clinical and genetic features related to poor prognosis in myelofibrosis.
format Online
Article
Text
id pubmed-9496754
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94967542022-09-23 Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients Kim, Tong-Yoon Kwag, Daehun Lee, Jong-Hyuk Lee, Joonyeop Min, Gi-June Park, Sung-Soo Park, Silvia Jeon, Young-Woo Yoon, Jae-Ho Shin, Seung-Hawn Yahng, Seung-Ah Cho, Byung-Sik Eom, Ki-Seong Kim, Yoo-Jin Lee, Seok Kim, Hee-Je Min, Chang-Ki Cho, Seok-Goo Lee, Jong-Wook Lee, Jong-Mi Kim, Myungshin Lee, Sung-Eun Cancers (Basel) Article SIMPLE SUMMARY: The final stages of myeloproliferative neoplasms (MPNs) are related to myelofibrosis (MF). This study aimed to compare secondary myelofibrosis (SMF), overt (PMF), and prefibrotic primary myelofibrosis (pre-PMF) and determine prognostic factors in clinical and genetic features. This study included 229 patients; 67 (29%), 122 (53%), and 40 (18%) cases were confirmed as SMF, overt PMF, and pre-PMF, respectively. We compare MFs, including pre-PMF, using six scoring stratifications associated with PMF and one scoring system with SMF. We also evaluated the impact of the genetic groups with clustering methods and previously reported genomic groups. We determined the clinical and genetic features associated with disease progression in SMF, overt PMF, and pre-PMF groups. ABSTRACT: The Philadelphia-negative myeloproliferative neoplasms (MPNs) are divided in three major groups: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 WHO classification incorporates also prefibrotic PMF (pre-PMF) and overt PMF. This study aimed to discriminate the clinical features, genetic alterations, and outcomes in patients with prefibrotic, overt PMF, and secondary MF (SMF). This study included 229 patients with diagnosed myelofibrosis (MF). Among 229 patients, 67 (29%), 122 (53%), and 40 (18%) were confirmed as SMF, overt PMF, and pre-PMF, respectively. The JAK2 V617F mutation was differentially distributed in SMF and PMF, contradictory to CALR and MPL mutations. Regarding nondriver mutations, the occurrence of ASXL1 mutations differed between PMF and SMF or pre-PMF. The three-year overall survival was 91.5%, 85.3%, and 94.8% in SMF, overt PMF, and pre-PMF groups. Various scoring systems could discriminate the overall survival in PMF but not in SMF and pre-PMF. Still, clinical features including anemia and thrombocytopenia were poor prognostic factors throughout the myelofibrosis, whereas mutations contributed differently. Molecular grouping by wild-type SF3B1 and SRSF2/RUNX1/U2AF1/ASXL1/TP53 mutations showed inferior progression-free survival (PFS) in PMF, SMF, and pre-PMF. We determined the clinical and genetic features related to poor prognosis in myelofibrosis. MDPI 2022-09-16 /pmc/articles/PMC9496754/ /pubmed/36139644 http://dx.doi.org/10.3390/cancers14184485 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Tong-Yoon
Kwag, Daehun
Lee, Jong-Hyuk
Lee, Joonyeop
Min, Gi-June
Park, Sung-Soo
Park, Silvia
Jeon, Young-Woo
Yoon, Jae-Ho
Shin, Seung-Hawn
Yahng, Seung-Ah
Cho, Byung-Sik
Eom, Ki-Seong
Kim, Yoo-Jin
Lee, Seok
Kim, Hee-Je
Min, Chang-Ki
Cho, Seok-Goo
Lee, Jong-Wook
Lee, Jong-Mi
Kim, Myungshin
Lee, Sung-Eun
Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
title Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
title_full Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
title_fullStr Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
title_full_unstemmed Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
title_short Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
title_sort clinical features, gene alterations, and outcomes in prefibrotic and overt primary and secondary myelofibrotic patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496754/
https://www.ncbi.nlm.nih.gov/pubmed/36139644
http://dx.doi.org/10.3390/cancers14184485
work_keys_str_mv AT kimtongyoon clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT kwagdaehun clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT leejonghyuk clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT leejoonyeop clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT mingijune clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT parksungsoo clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT parksilvia clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT jeonyoungwoo clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT yoonjaeho clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT shinseunghawn clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT yahngseungah clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT chobyungsik clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT eomkiseong clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT kimyoojin clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT leeseok clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT kimheeje clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT minchangki clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT choseokgoo clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT leejongwook clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT leejongmi clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT kimmyungshin clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients
AT leesungeun clinicalfeaturesgenealterationsandoutcomesinprefibroticandovertprimaryandsecondarymyelofibroticpatients